Publications & Posters

Poster

Interim Analysis of PROMise, a Clinical Study Combining the BET Inhibitor OPN-2853 with Ruxolitinib in Patients with Advanced Myelofibrosis Experiencing an Inadequate Response to Ruxolitinib

Download PDF
Oral Presentation

Novel Multifunctional Degraders of EP300/CBP and IKZF1/3 with Potent Anti-Myeloma Activity

Download PDF
Publication

Targeting TAZ-TEAD in minimal residual disease enhances the duration of targeted therapy in melanoma models

https://www.nature.com/articles/s41467-025-64682-7
Poster

Interim Analysis of PROMise, a Clinical Study Combining the BET Inhibitor OPN-2853 with Ruxolitinib in Patients with Advanced Myelofibrosis Experiencing an Inadequate Response to Ruxolitinib

Download PDF
Poster

OPN-6602, an Orally Bioavailable EP300/CBP Bromodomain Inhibitor, Targets Multiple Myeloma through Suppression of IRF4 and MYC

  • AUTHORS Matusow, et al
  • Programs OPN-6602
Download PDF
Poster

OPN-9840, a non-covalent potent pan-TEAD inhibitor, exhibits single agent efficacy in preclinical malignant mesothelioma models

Download PDF
Poster

OPN-6602, a potent dual EP300/CBP bromodomain inhibitor, targets multiple myeloma through concomitant suppression of IRF4 and c-MYC

  • AUTHORS Matusow, et al
  • Programs OPN-6602
Download PDF
Poster

OPN-6602, a dual EP300/CBP bromodomain inhibitor modulates androgen-driven transcription in mCRPC

  • AUTHORS Matusow, et al
  • Programs OPN-6602
Download PDF
Publication

Phase IIa Study of PLX2853 in Gynecologic Cancers with known ARID1A mutation and Phase Ib/IIa Study of PLX2853/Carboplatin in Platinum-resistant epithelial ovarian cancer

  • AUTHORS Duska, et al
  • Programs OPN-2853
https://ascopubs.org/doi/abs/10.1200/PO.23.00235
Poster

Phase 1b/2a clinical trial of the oral BET inhibitor PLX2853 as monotherapy for ARID1A mutated gynecologic cancers and in combination with carboplatin for platinum resistant ovarian cancer

  • AUTHORS Swisher, et al
  • Programs OPN-2853
Download PDF